PL2342182T3 - Pochodne izochinolinonu jako antagoniści NK3 - Google Patents

Pochodne izochinolinonu jako antagoniści NK3

Info

Publication number
PL2342182T3
PL2342182T3 PL09776285T PL09776285T PL2342182T3 PL 2342182 T3 PL2342182 T3 PL 2342182T3 PL 09776285 T PL09776285 T PL 09776285T PL 09776285 T PL09776285 T PL 09776285T PL 2342182 T3 PL2342182 T3 PL 2342182T3
Authority
PL
Poland
Prior art keywords
antagonists
isoquinolinone derivatives
isoquinolinone
derivatives
Prior art date
Application number
PL09776285T
Other languages
English (en)
Inventor
Nikolay Khanzhin
Karsten Juhl
Søren Møller Nielsen
Klaus Baek Simonsen
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41227186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2342182(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PL2342182T3 publication Critical patent/PL2342182T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09776285T 2008-09-15 2009-09-11 Pochodne izochinolinonu jako antagoniści NK3 PL2342182T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200801290 2008-09-15
DKPA200900010 2009-01-06
EP09776285A EP2342182B1 (en) 2008-09-15 2009-09-11 Isoquinolinone derivatives as nk3 antagonists
PCT/DK2009/050237 WO2010028655A1 (en) 2008-09-15 2009-09-11 Isoquinolinone derivatives as nk3 antagonists

Publications (1)

Publication Number Publication Date
PL2342182T3 true PL2342182T3 (pl) 2013-04-30

Family

ID=41227186

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09776285T PL2342182T3 (pl) 2008-09-15 2009-09-11 Pochodne izochinolinonu jako antagoniści NK3

Country Status (27)

Country Link
EP (1) EP2342182B1 (pl)
JP (1) JP5536776B2 (pl)
KR (1) KR101638641B1 (pl)
CN (1) CN102149685B (pl)
AR (1) AR073511A1 (pl)
AU (1) AU2009291309B2 (pl)
BR (1) BRPI0917245B8 (pl)
CA (1) CA2732612C (pl)
CL (1) CL2011000533A1 (pl)
CO (1) CO6351781A2 (pl)
CY (1) CY1113743T1 (pl)
DK (1) DK2342182T3 (pl)
EA (1) EA021581B1 (pl)
ES (1) ES2399177T3 (pl)
HR (1) HRP20130038T1 (pl)
IL (1) IL210236A (pl)
MX (1) MX2011001786A (pl)
MY (1) MY164998A (pl)
NZ (1) NZ591265A (pl)
PL (1) PL2342182T3 (pl)
PT (1) PT2342182E (pl)
RS (1) RS52674B (pl)
SI (1) SI2342182T1 (pl)
SM (1) SMT201300020B (pl)
TW (1) TWI454461B (pl)
WO (1) WO2010028655A1 (pl)
ZA (1) ZA201103119B (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008131779A1 (en) 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists
AR072198A1 (es) 2008-06-23 2010-08-11 Lundbeck & Co As H Derivados de isoquinolinona como antagonistas de nk3 y composiciones farmaceuticas que los contienen
AR073891A1 (es) 2008-10-20 2010-12-09 Lundbeck & Co As H Derivados de isoquinolinona antagonistas de receptores nk3, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de psicosis, alzheimer y otras enfermedades.
TW201143768A (en) 2009-12-15 2011-12-16 Lundbeck & Co As H Pyridone derivatives as NK3 antagonists
TW201144311A (en) * 2010-03-12 2011-12-16 Lundbeck & Co As H Azaisoquionolinone derivatives as NK3 antagonists
BR112014011173A2 (pt) 2011-11-09 2017-05-09 Abbvie Deutschland carboxamidas heterocíclicas úteis como inibidores de fosfodiesterase tipo 10a
JP2021522341A (ja) * 2018-04-27 2021-08-30 ソージャニックス, インコーポレイテッド イソキノリノンの多形及びアモルファス形態ならびにその使用方法
WO2023152888A1 (ja) * 2022-02-10 2023-08-17 カルナバイオサイエンス株式会社 フルオロイソキノリン化合物およびその製造法
CN116621755A (zh) * 2023-05-29 2023-08-22 山东玉满坤生物科技有限公司 一种吡拉西坦有关物质的合成方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9825554D0 (en) * 1998-11-20 1999-01-13 Smithkline Beecham Spa Novel Compounds
EP1385839B1 (en) * 2001-04-11 2006-02-22 GlaxoSmithKline S.p.A. 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
GB0509405D0 (en) * 2005-05-10 2005-06-15 Merck Sharp & Dohme Therapeutic compounds
WO2008131779A1 (en) * 2007-04-26 2008-11-06 H. Lundbeck A/S Isoquinolinone derivatives as nk3 antagonists

Also Published As

Publication number Publication date
KR101638641B1 (ko) 2016-07-11
SI2342182T1 (sl) 2013-04-30
CA2732612A1 (en) 2010-03-18
ES2399177T3 (es) 2013-03-26
BRPI0917245A2 (pt) 2015-11-10
JP2012502069A (ja) 2012-01-26
EA201170447A1 (ru) 2011-08-30
PT2342182E (pt) 2013-02-11
CO6351781A2 (es) 2011-12-20
TW201010979A (en) 2010-03-16
MX2011001786A (es) 2011-03-29
IL210236A0 (en) 2011-03-31
AU2009291309A1 (en) 2010-03-18
IL210236A (en) 2013-08-29
ZA201103119B (en) 2012-09-26
CN102149685B (zh) 2015-01-07
BRPI0917245A8 (pt) 2018-08-14
NZ591265A (en) 2013-02-22
EA021581B1 (ru) 2015-07-30
JP5536776B2 (ja) 2014-07-02
KR20110059849A (ko) 2011-06-07
TWI454461B (zh) 2014-10-01
CL2011000533A1 (es) 2011-08-26
MY164998A (en) 2018-02-28
EP2342182B1 (en) 2012-11-14
SMT201300020B (it) 2013-05-06
EP2342182A1 (en) 2011-07-13
BRPI0917245B1 (pt) 2020-07-28
BRPI0917245B8 (pt) 2021-05-25
AU2009291309B2 (en) 2014-07-17
CA2732612C (en) 2016-08-09
HRP20130038T1 (hr) 2013-02-28
AR073511A1 (es) 2010-11-10
RS52674B (sr) 2013-06-28
DK2342182T3 (da) 2013-02-04
WO2010028655A1 (en) 2010-03-18
CN102149685A (zh) 2011-08-10
CY1113743T1 (el) 2016-06-22

Similar Documents

Publication Publication Date Title
IL208466A0 (en) Isoquinolinone derivatives as nk3 antagonists
IL213676A0 (en) C5ar antagonists
ZA201103119B (en) Isoquinolinone derivatives as nk3 antagonists
ZA201001125B (en) Pyrrolidine Aryl-Ether as NK3 receptor antagonists
ZA201000676B (en) Pyrrolidine aryl-ether as NK3 receptor antagonists
IL213250A0 (en) 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2
IL212107A0 (en) Isoquinolinone derivatives as nk3 antagonists
IL209663A0 (en) Isoquinolinone derivatives as nk3 antagonists
IL213631A0 (en) Isoquinoline derivative
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL187410A0 (en) Quinoline derivatives as nk3 antagonists
ZA201008177B (en) Substituted quinazolines
IL200781A0 (en) Heterocycles as orexin antagonists
IL217759A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
IL207577A0 (en) Pyrrolidine ether derivatives as nk3 receptor antagonists
ZA201006563B (en) Novel tetrahydroisoquinoline derivative
GB0808944D0 (en) Substituted quinazolines
ZA201003169B (en) New non-peptide derivatives as bradykinin b1 antagonists
GB0808947D0 (en) Substituted quinazolines
ZA201005986B (en) Novel heterocycles
GB0808951D0 (en) Substituted quinazolines
GB0808950D0 (en) Substituted quinazolines
IL213763A0 (en) Pyrrolidine derivatives as nk3 receptor antagonists
GB0808953D0 (en) substituted quinazolines
GB0808952D0 (en) Substituted quinazolines